Antibody-dependent enhancement and the risk of HIV infection

Current HIV Research

Volumn 11, Issue 5, 2013, Pages 421-426

  Gorlani, Andrea ^a   Forthal, Donald N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADE; Complement; Enhancement; Fc R; HIV; Passive infusion and vaccine

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT RECEPTOR; EPITOPE; FC RECEPTOR; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NEVIRAPINE; PLACEBO; VIRUS ENVELOPE PROTEIN;

ADENOVIRUS 5; ANTIBODY DEPENDENT ENHANCEMENT; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; MACACA; MEN WHO HAVE SEX WITH MEN; NONHUMAN; REVIEW; RISK FACTOR; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIRUS INFECTIVITY;

AIDS VACCINES; ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION;

EID: 84889066727     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X113116660062     Document Type: Review

References (58)

1. Robinson WE, Montefiori DC, Mitchell WM. A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun 1987; 149(2): 693-9.
2. Robinson WE, Montefiori D, Mitchell W. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. The Lancet 1988; 331(8589): 790-4.
3. Robinson WE, Montefiori DC, Gillespie DH, Mitchell WM. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 1989; 2(1): 33-42.
4. Robinson WE, Montefiori DC, Mitchell WM. Complementmediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990; 175(2): 600-4.
5. Mouhoub A, Delibrias CC, Fischer E, Boyer V, Kazatchkine MD. Ligation of CR1 (C3b receptor, CD35) on CD4(+) T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996; 106(2): 297-303.
6. June RA, Schade SZ, Bankowski MJ, et al. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991; 5(3): 269-74.
7. Boyer V, Delibrias C, Noraz N, Fischer E, Kazatchkine MD, Desgranges C. Complement receptor type-2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol 1992; 36(6): 879-83.
8. Zhou J, Montefiori DC. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology 1996; 226(1): 13-21.
9. Tremblay M, Meloche S, Sekaly RP, Wainberg MA. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 1990; 171(5): 1791-6.
10. Robinson WE. Mechanism for complement-mediated, antibodydependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 2006; 19(3): 434-47.
11. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003; 13(6): 387-98.
12. Füst G, Prohászka Z, Hidvégi T, et al. Competition of complement proteins and specific antibodies for binding to HIV-1 envelope antigens. Acta Microbiol Immunol Hung 1994; 41: S27-S31.
13. Robinson WE, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 1990; 64(11): 5301-5.
14. Robinson WE, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 1991; 65(8): 4169-76.
15. Jiang SB, Lin K, Neurath AR. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med 1991; 174(6): 1557-63.
16. Beck Z, Brown BK, Matyas GR, Polonis VR, Rao M, Alving CR. Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement. Virology 2011; 412(2): 441-7.
17. Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, Robinson WE. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses 1995; 11(9): 1095-9.
18. Willey S, Aasa-Chapman MM, O'Farrell S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous nonneutralising antibodies at early stages of infection. Retrovirology 2011; 8(1): 16.
19. Tóth FD, Szabó B, Ujhelyi E, et al. Neutralizing and complementdependent enhancing antibodies in different stages of HIV infection. AIDS 1991; 5(3): 263-8.
20. Füst G, Tóth FD, Kiss J, Ujhelyi E, Nagy I, Bánhegyi D. Neutralizing and enhancing antibodies measured in complementrestored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS 1994; 8(5): 603-9.
21. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996; 73(1): 60-7.
22. Dolin R, Graham BS, Greenberg SB, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 1991; 114(2): 119-27.
23. Montefiori DC, Robinson WE, Hirsch VM, Modliszewski AA, Mitchell WM, Johnson PR. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 1990; 64(1): 113-9.
24. Mitchell WM, Torres J, Johnson PR, et al. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. AIDS 1995; 9(1): 27-34.
25. Staprans SI, Barry AP, Silvestri G, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004; 101(35): 13026-31.
26. Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242(4878): 580-3.
27. Takeda A, Ennis FA. FcR-mediated enhancement of HIV-1 infection by antibody. AIDS Res Hum Retrov 1990; 6(8): 999-1004.
28. Homsy J, Meyer M, Tateno M, Clarkson S, Levy JAJ. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 1989; 244(4910): 1357-60.
29. Laurence J, Saunders A, Early E, Salmon JE. Human immunodeficiency virus infection of monocytes: relationship to Fcgamma receptors and antibody-dependent viral enhancement. Immunology 1990; 70(3): 338-43.
30. Takeda A, Sweet RW, Ennis FA. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R. J Virol 1990; 64(11): 5605-10.
31. Trischmann H, Davis D, Lachmann PJ. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4. AIDS Res Hum Retroviruses 1995; 11(3): 343-52.
32. Kozlowski PA, Black KP, Shen L, Jackson S. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol 1995; 154(11): 6163-73.
33. Zeira M, Byrn RA, Groopman JE. Inhibition of Serum-Enhanced HIV-1 Infection of U937 Monocytoid Cells by Recombinant Soluble Cd4 and Anti-Cd4 Monoclonal Antibody. AIDS Res Hum Retroviruses 1990; 6(5): 629-39.
34. Perno CF, Baseler MW, Broder S, Yarchoan R. Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med 1990; 171(4): 1043-56.
35. Nottet HS, Janse I, De Vos NM, Bakker LJ, Visser MR, Verhoef J. Antibody mediated enhancement of HIV-1 infection of an EBVtransformed B cell line is CD4 dependent. Eur J Clin Invest 1992; 22(10): 670-5.
36. Connor RI, Dinces NB, Howell AL, Romet-Lemonne JL, Pasquali JL, Fanger MW. Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. Proc Natl Acad Sci USA 1991; 88(21): 9593-7.
37. Eaton AM, Ugen KE, Weiner DB, Wildes T, Levy JA. An antigp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res Hum Retroviruses 1994; 10(1): 13-8.
38. Kliks SC, Shioda T, Haigwood NL, Levy JA. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90(24): 11518-22.
39. Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. J Infect Dis 1992; 165(3): 545-8.
40. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fc receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120(14): 2836-42.
41. Schutten M, Andeweg AC, Bosch ML, Osterhaus AD. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol 1995; 41(1): 18-22.
42. Guillon C, Schutten M, Boers PHM, Gruters RA, Osterhaus ADME. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol 2002; 76(6): 2827-34.
43. Sullivan N, Sun Y, Binley J, et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998; 72(8): 6332-8.
44. Halstead SB, Chow JS, Marchette NJ. Immunological enhancement of dengue virus replication. Nat New Biol 1973; 243(122): 24-6.
45. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140(4): 527-33.
46. Giannecchini S, Isola P, Sichi O, et al. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 2002; 76(14): 6882-92.
47. Wang SZ-S, Rushlow KE, Issel CJ, et al. Enhancement of EIAV replication and disease by immunization with a baculovirusexpressed recombinant envelope surface glycoprotein. Virology 1994; 199(1): 247-51.
48. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65.
49. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191(5): 666-77.
50. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178(10): 6596-603.
51. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113(16): 3716-25.
52. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
53. NIH Discontinues Immunizations in HIV Vaccine Study. Available from: http://www. niaid. nih. gov/news/newsreleases/2013/Pages/HVTN50 5April2013. aspx. Accessed May 12, 2013.
54. Brouwer KC, Lal RB, Mirel LB, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal infants is HIV-1 infection. AIDS 2004; 18(8): 1187-94.
55. Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of motherto-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011; 58(4): 399-407.
56. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87(3): 1708-19.
57. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
58. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108(27): 11181-6.